Back to top
more

MannKind (MNKD)

(Real Time Quote from BATS)

$7.57 USD

7.57
908,046

+0.13 (1.75%)

Updated Nov 7, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

Humana (HUM) Rewards Shareholders With a 12.4% Dividend Hike

by Zacks Equity Research

Humana's (HUM) capital position with strong cash-generating abilities and a solid balance sheet will likely sustain its shareholder-friendly moves.

Here's What Could Help MannKind (MNKD) Maintain Its Recent Price Strength

by Zacks Equity Research

MannKind (MNKD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 40% and 35.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Tyvaso drive the top line in the quarter.

    MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Mednax (MD) Q2 Earnings Match Estimates

    by Zacks Equity Research

    Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up

    by Zacks Equity Research

    United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.

    What's in Store for United Therapeutics' (UTHR) Q2 Earnings?

    by Zacks Equity Research

    United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.

    Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?

    by Zacks Equity Research

    Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

    by Zacks Equity Research

    The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

    MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down

    by Zacks Equity Research

    United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.

    MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

    by Zacks Equity Research

    United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

    Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know

    by Zacks Equity Research

    MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

    by Zacks Equity Research

    United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

    United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

    by Zacks Equity Research

    United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

    Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.